• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Could nasal vaccines be the next big weapon against COVID-19?

February 3, 2022 By Sean Whooley

Mucosa and relevant structures
Mucosa and relevant structures. [Image from Wikipedia]
Because of the way they provide protection, nasal vaccines could be the best long-term way to prevent COVID-19 infection, according to experts cited in The New York Times.

The Times reported that India-based Bharat Biotech, which has the Covaxin COVID-19 vaccine authorized in India and elsewhere, has an experimental COVID-19 nasal vaccine that may offer even stronger protection than injectable vaccines.

Previous evidence has demonstrated that intranasal vaccines offer potential advantages over traditional intramuscular vaccines. They can stimulate immunoglobulin A production, which can avert infection, as noted in a 2021 Scientific American article. Intranasal vaccines would likely generate mucosal immunity, reducing the virus’s odds to take root in the respiratory tract as the coronavirus first lands in the mucosal linings of the airways.

The New York Times reports that at least a dozen other nasal vaccines are in development around the world, but Bharat Biotech’s offering represents potentially the first of the lot to become available after it won approval last month to begin a Phase 3 trial in India, with the nasal spray to be used a booster for people who have already received two doses of a COVID-19 vaccine.

Aside from the potential scientific benefits of the intranasal vaccine in the fight against the virus, the practical benefits further strengthen its case. Immunizing populations with a nasal or oral vaccine would be faster than injections, The New York Times said, as injections require skill and more time to administer. Additionally, a nasal vaccine would likely appeal more, particularly to children, compared to shots, and would alleviate the struggle surrounding shortages of needles, syringes and other components of injectable vaccines.

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: Bharat Biotech, coronavirus, COVID-19

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS